The tweet was deleted by the author.
But we saved everything 🙂.
Accuray has released 10-year results from the FRAME-PROSTATE trial, demonstrating that TomoTherapy image-guided, moderate hypofractionation radiotherapy after prostatectomy yields excellent overall survival rates and very low late gastrointestinal toxicity.
These findings could influence future post-surgical treatment options for prostate cancer patients, supporting wider consideration of TomoTherapy in clinical protocols. Further details from the trial may guide both clinicians and patients navigating post-prostatectomy care.
Accuray previously reported that helical TomoTherapy was associated with significantly reduced xerostomia compared to VMAT in advanced nasopharyngeal carcinoma patients, citing improved protection of parotid glands in clinical data from a separate study. In another development, the company unveiled the Radixact and Helix systems to expand options for flexible helical radiotherapy at ESTRO26. These technologies highlight Accuray’s ongoing efforts to advance precision cancer treatment.